Creutzfeldt Jakob Disease News and Research

RSS

Creutzfeldt–Jakob disease or CJD (sometimes incorrectly referred to as mad cow disease) is a degenerative neurological disorder (brain disease) that is incurable and invariably fatal. It is the most common among the types of transmissible spongiform encephalopathy found in humans.

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

MAVS prion-like proteins are involved in innate immunity: Discovery

A person's ability to battle viruses at the cellular level remarkably resembles the way deadly infectious agents called prions misfold and cluster native proteins to cause disease, UT Southwestern Medical Center researchers report.

9 Aug 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

PrioNet Canada awards University of Western Ontario $600,000 to study neurodegenerative disorders

The University of Western Ontario is one of nine universities which will share 2.9 million dollars in research grants announced by PrioNet Canada to study Prion diseases and neurodegenerative disorders including Alzheimer's.

21 Jul 2011

Researchers identify altered expression of endogenous retroviruses in BSE-infected macaques

Prion diseases such as Creutzfeldt-Jakob disease in humans and bovine spongiform encephalopathy (BSE) in cattle are transmissible neurodegenerative diseases linked to the aggregation of the prion protein in the central nervous system.

1 Jul 2011

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.

14 Jun 2011

Researchers to examine risks and benefits of blood transfusions

Risks associated with blood transfusions are to be scrutinized in a new national project that will inform public policy on the process.

13 Jun 2011

Travel, hunting, and venison consumption linked to prion diseases

Researchers from the Centers for Disease Control and Prevention have examined the potential for human exposure to prion diseases, looking at hunting, venison consumption, and travel to areas in which prion diseases have been reported in animals.

23 May 2011

CSEW fails to protect public health by refusing to take part in variant Creutzfeldt-Jakob disease study

The creation of a post-mortem tissue archive for a study of the human form of mad cow disease failed because of a "misguided" refusal by coroners to participate.

9 May 2011

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.

From Baxter International Inc. 12 Apr 2011

Welsh CJD alert after two years of exposure

Thirty-eight people have been told they may have been put at risk of contracting the fatal brain disease Creutzfeldt-Jakob disease (CJD) following surgery. All the patients were operated on between 2007 and 2009 at either Swansea's Morriston or Singleton hospital, Neath Port Talbot or Princess of Wales Hospital in Bridgend.

29 Mar 2011

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Data presented by CSL Behring today suggest that treatment with higher dose Hizentra correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies.

22 Mar 2011

New research may shed light on possible treatments for prion diseases

New research by Chongsuk Ryou, researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology and molecular genetics in the UK College of Medicine, may shed light on possible treatments for prion diseases.

15 Mar 2011

First disease-specific biomarker for sporadic Creutzfeldt-Jakob disease identified

Neena Singh, MD, PhD and colleagues at Case Western Reserve University School of Medicine have identified the first disease-specific biomarker for sporadic Creutzfeldt-Jakob disease (sCJD), a universally fatal, degenerative brain disease for which there is no cure. sCJD is one of the causes of dementia and typically leads to death within a year of disease onset.

10 Mar 2011

Grifols receives FDA approval for Alphanate to treat vCJD

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it received approval from the US Food and Drug Administration for revised labeling for Alphanate Antihemophilic Factor/von Willebrand Factor Complex indicating that certain manufacturing steps have been shown to reduce the infectivity of a experimental TSE agent that is a model for variant Creutzfeldt Jakob Disease.

5 Mar 2011

FDA approves sBLA for CSL's Hizentra to treat PI

CSL Behring announced today that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra, Immune Globulin Subcutaneous, 20% Liquid, from 24 months to 30 months.

24 Feb 2011

Aminothiazoles as therapeutic leads for prion diseases

Scientists who examined more than 10,000 chemical compounds during the last year in search of potential new drugs for a group of untreatable brain diseases, are reporting that one substance shows unusual promise.

24 Feb 2011

How Huntington's disease proteins move from cell to cell

One bad apple is all it takes to spoil the barrel. And one misfolded protein may be all that's necessary to corrupt other proteins, forming large aggregations linked to several incurable neurodegenerative diseases such as Huntington's, Parkinson's and Alzheimer's.

19 Feb 2011

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Corifact™, Factor XIII Concentrate (Human), for the routine prophylactic treatment of congenital factor XIII (FXIII) deficiency. Corifact, already available for use in 12 countries throughout the world under the trade name Fibrogammin®- P, is the first and only FXIII concentrate approved in the U.S.